| Property | Value |
|---|
|
?:abstract
|
-
Introduction: Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of nucleic acid that play a role in prokaryotic defense and form the basis of a genome editing technology that allows permanent alteration of genetic material. This methodology, known as CRISPR-Cas9, is poised to revolutionize molecular biology, but no literature yet exists on how these advances will affect hospitalists. Areas covered: These specialists in inpatient medicine care for a wide variety of hospitalized patients, including those with infectious disease, cancer, cardiovascular disease, autoimmune disease, hematologic disease, and a variety of other conditions that may soon be impacted by advances in gene-modifying technology provided by CRISPR-Cas9. A Literature search was performed using PubMed [1 December 2019–17 April 2020]. Expert opinion: This paper reviews the remarkable diagnostic and therapeutic potential of the CRISPR-Cas9 platform and concludes with a look at ethical issues and technical hurdles pertaining to the implementation of permanent gene modification in the practice of Hospital Medicine.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
-
10.1080/14787210.2020.1761333
|
|
?:journal
|
-
Expert_Rev_Anti_Infect_Ther
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/7dd2e6c02841a9825ce5fa560ddd0ba7296cec85.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7212535.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}